Önder BOZDOĞAN, Pınar ATASOY, Mukadder KOÇAK, Nazan BOZDOĞAN, Tarık ÇAVUŞOĞLU, Mustafa Emre ERCİN

Hypoxic Gene Signature of Primary and Metastatic Melanoma Cell Lines: Focusing on HIF-1β and NDRG-1

Background: Hypoxia is an important microenvironmental factorsignificantly affecting tumor proliferation and progression. Theimportance of hypoxia is, however, not well known in oncogenesis ofmalignant melanoma.Aims: To evaluate the difference of hypoxic gene expressionsignatures in primary melanoma cell lines and metastatic melanomacell lines and to find the expression changes of hypoxia-related genesin primary melanoma cell lines at experimental hypoxic conditionsStudy Design: Cell study.Methods: The mRNA expression levels of hypoxia-related genes inprimary melanoma cell lines and metastatic melanoma cell lines and atexperimental hypoxic conditions in primary melanoma cell lines wereevaluated by using real-time polymerase chain reaction. Dependingon the experimental data, we focused on two genes/proteins,the hypoxia-inducible factor-1 beta and the N-myc downstreamregulated gene-1. The expression levels of the two proteins wereinvestigated by immunohistochemistry methods in 16 primary andmetastatic melanomas, 10 intradermal nevi, and a commercial tissuearray comprised of 208 cores including 192 primary and metastaticmalignant melanomas.Results: The real-time polymerase chain reaction study showedthat hypoxic gene expression signature was different betweenmetastatic melanoma cell lines and primary melanoma cell lines.Hypoxic experimental conditions significantly affected the hypoxicgene expression signature. In immunohistochemical study, N-mycdownstream regulated gene-1 expression was found to be lowerin primary cutaneous melanoma compared to in intradermal nevi(p=0.001). In contrast, the cytoplasmic expression of hypoxiainducible factor-1 beta was higher in primary cutaneous melanomathan in intradermal nevi (p=0.001). We also detected medium/strongsignificant correlations between the two proteins studied in the studygroups.Conclusion: Hypoxic response consists of closely related proteins inmore complex pathways. These findings will shed light on hypoxicprocesses in melanoma and unlock a Pandora’s box for developmentof new therapeutic strategies.

PDF

___

1. Bandarchi B, Jabbari CA, Vedadi A, Navab R. Molecular biology of normal melanocytes and melanoma cells. J Clin Pathol 2013;66:644-8.
2. Jäger K, Larribère L, Wu H, Weiss C, Gebhardt C, Utikal J. Expression of Neural Crest Markers GLDC and ERRFI1 is Correlated with Melanoma Prognosis. Cancer (Basel) 2019:11.
3. Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 2012;5:739-53.
4. Zhang Y, Fu X, Qi Y, Gao Q. A study of the clinical characteristics and prognosis of advanced mucosal and cutaneous melanoma in a Chinese population. Immunotherapy 2019;11:91-9.
5. Panda S, Dash S, Besra K, Samantaray S, Pathy P, Rout N. Clinicopathological study of malignant melanoma in a regional cancer center. Indian J Cancer 2018;55:292-6.
6. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park 2009;23:488-96.
7. Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B. LongTerm Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. J Oncol 2019;2019:5269062.
8. Brandner JM, Haass NK. Melanoma's connections to the tumour microenvironment. Pathology 2013;45:443-52.
9. Yan Y, Leontovich AA, Gerdes MJ, Desai K, Dong J, Sood A, et al. Understanding heterogeneous tumor microenvironment in metastatic melanoma. PLoS One 2019;14:0216485.
10. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, et al. Hypoxiainducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000;60:4010-5.
11. Favaro E, Lord S, Harris AL, Buffa FM. Gene expression and hypoxia in breast cancer. Genome Med 2011;3:55.
12. Tsai YP, Wu KJ. Hypoxia-regulated target genes implicated in tumor metastasis. J Biomed Sci 2012;19:102.
13. Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, et al. Molecular landmarks of tumor hypoxia across cancer types. Nature Genet 2019;51:308-18.
14. Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 2005;8:443-54.
15. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 2013;123:3664-71.
16. Lee HJ, Jung YH, Choi GE, Kim JS, Chae CW, Han HJ. Role of HIF1α Regulatory Factors in Stem Cells. Int J Stem Cells 2019;12:8-20.
17. Mandl M, Kapeller B, Lieber R, Macfelda K. Hypoxia-inducible factor-1β (HIF-1β) is upregulated in a HIF-1α-dependent manner in 518A2 human melanoma cells under hypoxic conditions. Biochem Biophys Res Commun 2013;434:166-72.
18. Mylonis I, Simos G, Paraskeva E. Hypoxia-Inducible Factors and the Regulation of Lipid Metabolism. Cells 2019:8.
19. Bonazzi VF, Stark MS, Hayward NK. MicroRNA regulation of melanoma progression. Melanoma Res 2012;22:101-13.
20. Vaupel P. The Role of Hypoxia-Induced Factors in Tumor Progression. Oncologist. 2004;9(Suppl 5):10-7.
21. Campillo N, Falcones B, Otero J, Colina R, Gozal D, Navajas D, et al. Differential Oxygenation in Tumor Microenvironment Modulates Macrophage and Cancer Cell Crosstalk: Novel Experimental Setting and Proof of Concept. Front Oncol 2019;9:43.
22. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use of a Monoclonal Anti-Estrogen Receptor Antibody in the Immunohistochemical Evaluation of Human Tumors. Cancer Res 1986;46(8 Suppl):4244-8
23. Saxena K, Jolly MK. Acute vs. Chronic vs. Cyclic Hypoxia: Their Differential Dynamics, Molecular Mechanisms, and Effects on Tumor Progression. Biomolecules 2019:9.
24. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, et al. Hypoxiainducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000;60:4010-5.
25. Chipurupalli S, Kannan E, Tergaonkar V, D'Andrea R, Robinson N. Hypoxia Induced ER Stress Response as an Adaptive Mechanism in Cancer. Int J Mol Sci 2019:20.
26. Koh SS, Wei JP, Li X, Huang RR, Doan NB, Scolyer RA, et al. Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Mod Pathol 2012;25:828-37.
27. Zhang B, Kasoju N, Li Q, Soliman E, Yang A, Cui Z, et al. Culture surfaces induce hypoxia-regulated genes in human mesenchymal stromal cells. Biomed Mater 2019;14:035012.
28. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008;214:559-67.
29. Lian L, Li XL, Xu MD, Li XM, Wu MY, Zhang Y, et al. VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer. BMC Cancer 2019;19:183.
30. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 2015;15:7-24.
31. Cevenini A, Orrù S, Mancini A, Alfieri A, Buono P, Imperlini E. Molecular Signatures of the Insulin-like Growth Factor 1-mediated Epithelial-Mesenchymal Transition in Breast, Lung and Gastric Cancers. Int J Mol Sci 2018:19.
32. Aikawa T, Whipple CA, Lopez ME, Gunn J, Young A, Lander AD, et al. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J Clin Invest 2008;118:89-99.
33. Wang S, Qiu Y, Bai B. The Expression, Regulation, and Biomarker Potential of Glypican-1 in Cancer. Front Oncol 2019;9:614.
34. Bertucci F, Pages C, Finetti P, Rochaix P, Lamant L, Devilard E, et al. Gene expression profiling of human melanoma cell lines with distinct metastatic potential identifies new progression markers. Anticancer Res 2007;27:3441-9.
35. Campillo N, Falcones B, Otero J, Colina R, Gozal D, Navajas D, et al. Differential Oxygenation in Tumor Microenvironment Modulates Macrophage and Cancer Cell Crosstalk: Novel Experimental Setting and Proof of Concept. Front Oncol 2019;9:43.
36. Jeffs AR, Glover AC, Slobbe LJ, Wang L, He S, Hazlett JA, et al. A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One 2009;4:8461.
37. Ridley AJ. Rho GTPase signalling in cell migration. Curr Opin Cell Biol 2015;36:103-12.
38. Zhu GF, Xu YW, Li J, Niu HL, Ma WX, Xu J, et al. Mir20a/106a-WTX axis regulates RhoGDIa/CDC42 signaling and colon cancer progression. Nat Commun 2019;10:112.
39. Zhou H, Huang S. Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis. Curr Protein Pept Sci 2011;12:30-42.
40. Conciatori F, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, et al. Role of mTOR Signaling in Tumor Microenvironment: An Overview. Int J Mol Sci 2018:19.
41. Zagorska A, Dulak J. HIF-1: the knowns and unknowns of hypoxia sensing. Acta Biochim Pol 2004;51:563-85.
42. Chilov D, Camenisch G, Kvietikova I, Ziegler U, Gassmann M, Wenger RH. Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1alpha. J Cell Sci 1999;112:1203-12.
43. Corre S, Tardif N, Mouchet N, Leclair HM, Boussemart L, Gautron A, et al. Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. Nat Commun 2018;9:4775.
44. Mandl M, Depping R. Hypoxia-Inducible Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) (HIF-1β): is it a rare exception? Mol Med 2014;20:215-20.
45. Cangul H, Salnikow K, Yee H, Zagzag D, Commes T, Costa M. Enhanced overexpression of an HIF-1/hypoxia-related protein in cancer cells. Environ Health Perspect 2002;110(Suppl 5):783-8.
46. Bae DH, Jansson PJ, Huang ML, Kovacevic Z, Kalinowski D, Lee CS, et al. The role of NDRG1 in the pathology and potential treatment of human cancers. J Clin Pahol 2013;66:911-7.
47. Yeh CC, Luo JL, Nhut Phan N, Cheng YC, Chow LP, Tsai MH, et al. Different effects of long noncoding RNA NDRG1-OT1 fragments on NDRG1 transcription in breast cancer cells under hypoxia. RNA Biol 2018;15:1487-98.
48. Konstantakou EG, Velentzas AD, Anagnostopoulos AK, Litou ZI, Konstandi OA, Giannopoulou AF, et al. Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets. PLOS ONE 2017;12:e0171512.
49. Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet 2004;5:27.